Literature DB >> 28363324

Sociodemographic predictors of variation in coverage of the national shingles vaccination programme in England, 2014/15.

Charlotte Ward1, Lisa Byrne2, Joanne M White2, Gayatri Amirthalingam2, Karen Tiley2, Michael Edelstein2.   

Abstract

INTRODUCTION: In September 2013, England introduced a shingles vaccination programme to reduce incidence and severity of shingles in the elderly. This study aims to assess variation in vaccine coverage with regards to selected sociodemographic factors to inform activities for improving equity of the programme.
METHODS: Eligible 70year-olds were identified from a national vaccine coverage dataset in 2014/15 that includes 95% of GPs in England. NHS England Local Team (LT) and index of multiple deprivation (IMD) scores were assigned to patients based on GP-postcode. Vaccine coverage (%) with 95% confidence intervals (CIs), were calculated overall and by LT, ethnicity and IMD, using binomial regression.
RESULTS: Of 502,058 eligible adults, 178,808 (35.6%) had ethnicity recorded. Crude vaccine coverage was 59.5% (95%CI: 59.3-59.7). Coverage was lowest in London (49.6% coverage, 95%CI: 49.0-50.2), and compared to this coverage was significantly higher in all other LTs (+6.3 to +10.4, p<0.001) after adjusting for ethnicity and IMD. Coverage decreased with increasing deprivation and was 8.2% lower in the most deprived (95%CI: 7.3-9.1) compared with the least deprived IMD quintile (64.1% coverage, 95%CI: 63.6-64.6), after adjustment for ethnicity and LT. Compared with White-British (60.7% coverage, 95%CI: 60.5-61.0), other ethnic groups had between 4.0% (Indian) and 21.8% (Mixed: White and Black African) lower coverage. After adjusting for IMD and LT, significantly lower coverage by ethnicity persisted in all groups, except in Mixed: Other, Indian and Bangladeshi compared with White-British.
CONCLUSIONS: After taking geography and deprivation into account, shingles vaccine coverage varied by ethnicity. White-British, Indian and Bangladeshi groups had highest coverage; Mixed: White and Black African, and Black-other ethnicities had the lowest. Patients' ethnicity and IMD are predictors of coverage which contribute to, but do not wholly account for, geographical variation coverage. Interventions to address service-related, sociodemographic and ethnic inequalities in shingles vaccine coverage are required.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Coverage; Deprivation; England; Ethnicity; Inequalities; Shingles immunisation; Vaccine

Mesh:

Substances:

Year:  2017        PMID: 28363324     DOI: 10.1016/j.vaccine.2017.03.042

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Zoster vaccination inequalities: A population based cohort study using linked data from the UK Clinical Practice Research Datalink.

Authors:  Anu Jain; Jemma L Walker; Rohini Mathur; Harriet J Forbes; Sinéad M Langan; Liam Smeeth; Albert J van Hoek; Sara L Thomas
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

2.  Determinants of shingles vaccine acceptance in the United Kingdom.

Authors:  Hélène Bricout; Laurence Torcel-Pagnon; Coralie Lecomte; Mariana F Almas; Ian Matthews; Xiaoyan Lu; Ana Wheelock; Nick Sevdalis
Journal:  PLoS One       Date:  2019-08-01       Impact factor: 3.240

3.  What is the cost of delivering routine vaccinations at GP practices in England? A comparative time-driven activity-based costing analysis.

Authors:  Tim Crocker-Buque; Kitty Mohan; Mary Ramsay; Michael Edelstein; Sandra Mounier-Jack
Journal:  Hum Vaccin Immunother       Date:  2019-06-14       Impact factor: 3.452

4.  Herpes zoster in older adults in Ontario, 2002-2016: Investigating incidence and exploring equity.

Authors:  Sarah A Buchan; Nick Daneman; Jun Wang; Sarah E Wilson; Gary Garber; Anne E Wormsbecker; Tony Antoniou; Shelley L Deeks
Journal:  PLoS One       Date:  2021-02-11       Impact factor: 3.240

5.  Characteristics associated with COVID-19 vaccine uptake among adults aged 50 years and above in England (8 December 2020-17 May 2021): a population-level observational study.

Authors:  Elise Tessier; Yuma Rai; Eleanor Clarke; Anissa Lakhani; Camille Tsang; Ashley Makwana; Heather Heard; Tim Rickeard; Shreya Lakhani; Partho Roy; Michael Edelstein; Mary Ramsay; Jamie Lopez-Bernal; Joanne White; Nick Andrews; Colin N J Campbell; Julia Stowe
Journal:  BMJ Open       Date:  2022-03-01       Impact factor: 2.692

Review 6.  Access to Vaccination among Disadvantaged, Isolated and Difficult-to-Reach Communities in the WHO European Region: A Systematic Review.

Authors:  Winifred Ekezie; Samy Awwad; Arja Krauchenberg; Nora Karara; Łukasz Dembiński; Zachi Grossman; Stefano Del Torso; Hans Juergen Dornbusch; Ana Neves; Sian Copley; Artur Mazur; Adamos Hadjipanayis; Yevgenii Grechukha; Hanna Nohynek; Kaja Damnjanović; Milica Lazić; Vana Papaevangelou; Fedir Lapii; Chen Stein-Zamir; Barbara Rath
Journal:  Vaccines (Basel)       Date:  2022-06-28

7.  Recording of 'COVID-19 vaccine declined': a cohort study on 57.9 million National Health Service patients' records in situ using OpenSAFELY, England, 8 December 2020 to 25 May 2021.

Authors:  Helen J Curtis; Peter Inglesby; Brian MacKenna; Richard Croker; William J Hulme; Christopher T Rentsch; Krishnan Bhaskaran; Rohini Mathur; Caroline E Morton; Sebastian Cj Bacon; Rebecca M Smith; David Evans; Amir Mehrkar; Laurie Tomlinson; Alex J Walker; Christopher Bates; George Hickman; Tom Ward; Jessica Morley; Jonathan Cockburn; Simon Davy; Elizabeth J Williamson; Rosalind M Eggo; John Parry; Frank Hester; Sam Harper; Shaun O'Hanlon; Alex Eavis; Richard Jarvis; Dima Avramov; Paul Griffiths; Aaron Fowles; Nasreen Parkes; Stephen Jw Evans; Ian J Douglas; Liam Smeeth; Ben Goldacre
Journal:  Euro Surveill       Date:  2022-08

8.  A process evaluation of how the routine vaccination programme is implemented at GP practices in England.

Authors:  Tim Crocker-Buque; Michael Edelstein; Sandra Mounier-Jack
Journal:  Implement Sci       Date:  2018-10-22       Impact factor: 7.327

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.